It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Embryonic stem cell (ESC) fate decisions are regulated by a complex circuitry that coordinates gene expression at multiple levels from chromatin to mRNA processing. Recently, ribosome biogenesis and translation have emerged as key pathways that efficiently control stem cell homeostasis, yet the underlying molecular mechanisms remain largely unknown. Here, we identified RSL24D1 as highly expressed in both mouse and human pluripotent stem cells. RSL24D1 is associated with nuclear pre-ribosomes and is required for the biogenesis of 60S subunits in mouse ESCs. Interestingly, RSL24D1 depletion significantly impairs global translation, particularly of key pluripotency factors and of components from the Polycomb Repressive Complex 2 (PRC2). While having a moderate impact on differentiation, RSL24D1 depletion significantly alters ESC self-renewal and lineage commitment choices. Altogether, these results demonstrate that RSL24D1-dependant ribosome biogenesis is both required to sustain the expression of pluripotent transcriptional programs and to silence PRC2-regulated developmental programs, which concertedly dictate ESC homeostasis.
Pluripotency is coordinated at multiple levels of gene expression. Here the authors show that ribosome biogenesis is tightly regulated in embryonic stem cells (ESC) to control the translation of transcription and chromatin factors and dictate ESC fate.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Université Claude Bernard Lyon I, Centre Léon Bérard, Cancer Initiation and Tumoral Cell Identity (CITI) Department. Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174); Institut Convergence Plascan, Lyon, France (GRID:grid.418116.b); Labex Dev2Can, Lyon, France (GRID:grid.418116.b)
2 Université Claude Bernard Lyon I, Centre Léon Bérard, Cancer Initiation and Tumoral Cell Identity (CITI) Department. Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174)
3 Université Claude Bernard Lyon I, Centre Léon Bérard, Cancer Initiation and Tumoral Cell Identity (CITI) Department. Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174); Institut Convergence Plascan, Lyon, France (GRID:grid.418116.b); Labex Dev2Can, Lyon, France (GRID:grid.418116.b); Inovarion, Paris, France (GRID:grid.418116.b)
4 University of Ottawa, Dept. of Biochemistry, Microbiology and Immunology, Faculty of Medicine, Ottawa, Canada (GRID:grid.28046.38) (ISNI:0000 0001 2182 2255); National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Canada (GRID:grid.24433.32) (ISNI:0000 0004 0449 7958)
5 Laboratoire de Biologie et de Modélisation de la Cellule, ENS de Lyon, CNRS UMR 5239, Inserm U1293, Lyon, France (GRID:grid.462957.b) (ISNI:0000 0004 0598 0706)
6 Université Claude Bernard Lyon I, Centre Léon Bérard, Cancer Initiation and Tumoral Cell Identity (CITI) Department. Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174); Institut Convergence Plascan, Lyon, France (GRID:grid.418116.b); Labex Dev2Can, Lyon, France (GRID:grid.418116.b); Equipe labellisée la Ligue contre le cancer, Lyon, France (GRID:grid.418116.b)
7 Université Claude Bernard Lyon I, Centre Léon Bérard, Cancer Initiation and Tumoral Cell Identity (CITI) Department. Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174); Institut Convergence Plascan, Lyon, France (GRID:grid.418116.b)
8 Université Claude Bernard Lyon I, Centre Léon Bérard, Cancer Initiation and Tumoral Cell Identity (CITI) Department. Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174); Institut Convergence Plascan, Lyon, France (GRID:grid.418116.b); Hospices Civils de Lyon, Neuro-oncology department, Lyon, France (GRID:grid.413852.9) (ISNI:0000 0001 2163 3825)
9 University Grenoble Alpes, INSERM, CEA, UA13 BGE, CNRS, CEA, FR2048, 38000, Grenoble, France (GRID:grid.457348.9) (ISNI:0000 0004 0630 1517)
10 Université Claude Bernard Lyon I, Centre Léon Bérard, Cancer Initiation and Tumoral Cell Identity (CITI) Department. Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France (GRID:grid.418116.b) (ISNI:0000 0001 0200 3174); Institut Convergence Plascan, Lyon, France (GRID:grid.418116.b); Institut de Pathologie Est, Hospices Civils de Lyon, Lyon, France (GRID:grid.413852.9) (ISNI:0000 0001 2163 3825)